By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
CFP
An mRNA vaccine for Epstein-Barr virus positive tumors has been approved by China's Center for Drug Evaluation of the National Medical Products Administration for Phase-I clinical trials.
The new injection, independently developed by WestGene Biopharma in Chengdu, southwest China's Sichuan Province, received the Investigational New Drug approval from the U.S. Food and Drug Administration in May this year and Investigator-Initiated Trials in nasopharyngeal carcinoma and lymphoma have been completed.
Epstein-Barr virus was identified as a Group-I carcinogen by the International Agency for Research on Cancer, said Song Xiangrong, a co-founder of WestGene Biopharma, adding that it was the first human oncogenic virus to be discovered.
The virus is correlated with more than 10 types of malignant tumors such as nasopharyngeal carcinoma, lymphoma and gastric cancer, said Song. Development of an mRNA tumor therapeutic vaccine is one of the major breakthroughs in the field of mRNA innovative drugs and tumor immunotherapy.
The company will conduct clinical trials across the country to promote the application of the mRNA vaccine as soon as possible.